Hims is one of the many platforms that offer telehealth online from licensed providers, with services spanning from skincare and hair loss to anxiety and erectile dysfunction. In this review ...

Hims & Hers Health, Inc. (HIMS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea ...

Hims & Hers (HIMS) stock price remained on edge even after the fast-growing telehealth company published strong financial ...

There is also a chance that a weaker macroeconomy and slowing consumer spending may encourage more consumers to review their ...

Hims & Hers Health, Inc. HIMS delivered an earnings per share (EPS) of 32 cents in third-quarter 2024 against the year-ago ...

If you’re looking to prevent hair loss or stop the progression of any hair loss that’s started, a topical product can help.

Telehealth platform Hims & Hers will begin offering a generic version of liraglutide, a GLP-1 weight loss drug, to its customers in 2025, Quartz reported Nov. 4.

Hims & Hers Health, Inc. (HIMS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term ...

While Hims, Inc. has an A+ rating with the Better Business Bureau, some customer reviews are less than stellar. As of August 2024, the company’s overall 3.86 average rating out of 5 stars has to ...

Hims & Hers Health, Inc. ("Hims & Hers" or the "Company", NYSE: HIMS), the leading health and wellness platform, today announced financial results for the third quarter ended September 30, 2024 in a ...

Hims & Hers Health Inc ... Give directly to The Spokesman-Review's Northwest Passages community forums series -- which helps to offset the costs of several reporter and editor positions at ...

Hims & Hers Health (HIMS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Cherny from Leerink Partners reiterated a Hold rating on ...